Amphotericin b and Repaglinide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Amphotericin b (amphotericin b) and Repaglinide (repaglinide). Common drug interactions include pancreatitis acute among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Amphotericin b and Repaglinide. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Amphotericin b?

Amphotericin b has active ingredients of amphotericin b. It is often used in thrush. eHealthMe is studying from 16,275 Amphotericin b users. Check the latest studies of Amphotericin b.

What is Repaglinide?

Repaglinide has active ingredients of repaglinide. It is often used in diabetes. eHealthMe is studying from 8,226 Repaglinide users. Check the latest studies of Repaglinide.



On Jul, 17, 2026

15 people who take Amphotericin b and Repaglinide together, and have interactions are studied.

Amphotericin b and Repaglinide drug interactions.

What are the common drug interactions of Amphotericin B and Repaglinide, by gender? *:

female:

  1. Pancreatitis acute (sudden inflammation of pancreas)
  2. Anaemia (lack of blood)
  3. Renal failure (kidney dysfunction)
  4. Zygomycosis (an infection caused by fungus)
  5. Atypical pneumonia (acute respiratory disease marked by high fever and coughing)
  6. Neutropenia (an abnormally low number of neutrophils)
  7. Neutropenic infection (infection with less neutrophil numbers in blood)
  8. Septic shock (shock due to blood infection)
  9. Sinusitis (inflammation of sinus)
  10. Type 2 diabetes mellitus

male:

  1. Dyspnoea (difficult or laboured respiration)
  2. Anaemia (lack of blood)
  3. Chest pain
  4. Chills (felling of cold)
  5. Constipation
  6. Dizziness
  7. Epistaxis (bleed from the nose)
  8. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  9. Hypoacusis (loss of hearing)
  10. Hypokalaemia (low potassium)

What are the common drug interactions of Amphotericin B and Repaglinide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Dyspnoea (difficult or laboured respiration)
  2. Anaemia (lack of blood)
  3. Blood bilirubin increased
  4. Blood pressure decreased
  5. Cough
  6. Hyperglycaemia (high blood sugar)
  7. Pleuritic pain
  8. Neutropenia (an abnormally low number of neutrophils)
  9. Agitation (state of anxiety or nervous excitement)
  10. Arthralgia (joint pain)

60+:

  1. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  2. Pancreatitis acute (sudden inflammation of pancreas)
  3. Septic shock (shock due to blood infection)
  4. Cytomegalovirus infection
  5. Diarrhoea
  6. Leukopenia (less number of white blood cells in blood)
  7. Pneumonia
  8. Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
  9. Benign prostatic hyperplasia (benign enlargement of the prostate)
  10. Febrile neutropenia (fever with reduced white blood cells)

What are the existing conditions these people have? *

  1. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 26.67%
  2. Constipation: 4 people, 26.67%
  3. Fever: 4 people, 26.67%
  4. Abdominal Pain: 3 people, 20.00%
  5. Fungal Infection: 3 people, 20.00%
  6. High Blood Pressure: 3 people, 20.00%
  7. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 13.33%
  8. Fungal Oesophagitis (fungal inflammation of the oesophagus): 2 people, 13.33%
  9. Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 1 person, 6.67%
  10. Anaemia (lack of blood): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Amphotericin b and Repaglinide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Amphotericin b and Repaglinide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Amphotericin b:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Repaglinide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Amphotericin b and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Repaglinide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on amphotericin b and repaglinide (the active ingredients of Amphotericin b and Repaglinide, respectively), and Amphotericin b and Repaglinide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: